We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+21.39%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$308M
AUM Growth
+$65.9M
Cap. Flow
+$53.9M
Cap. Flow %
17.47%
Top 10 Hldgs %
62.02%
Holding
42
New
12
Increased
6
Reduced
4
Closed
13

Top Buys

Rank Stock Value
1
VOR icon
Vor Biopharma
VOR
+$25.5M
2
IRON icon
Disc Medicine
IRON
+$21.1M
3
RAPT
RAPT Therapeutics
RAPT
+$18M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$9.87M
5
SLNO
Soleno Therapeutics
SLNO
+$9.6M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
2
ABVX
Abivax
ABVX
+$12.7M
3
RZLT icon
Rezolute
RZLT
+$11.8M
4
CYTK icon
Cytokinetics
CYTK
+$8.24M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$8.03M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
1
Apogee Therapeutics
APGE
$10.2B
$28.2M 9.15%
374,000
+70,000
+23% +$4.41M
AMLX icon
2
Amylyx Pharmaceuticals
AMLX
$2.05B
$21.1M 6.85%
1,750,000
+50,000
+3% +$679K
ZURA icon
3
Zura Bio
ZURA
$497M
$20M 6.48%
3,815,930
– –
IRON icon
4
Disc Medicine
IRON
$2.83B
$19.9M 6.44%
+250,000
New +$21.1M
RAPT
5
DELISTED
RAPT Therapeutics
RAPT
$19.7M 6.38%
+581,187
New +$18M
IMVT icon
6
Immunovant
IMVT
$8.09B
$19.1M 6.18%
750,000
+250,000
+50% +$5.57M
SLNO
7
DELISTED
Soleno Therapeutics
SLNO
$18.5M 6%
400,000
+175,000
+78% +$9.6M
VOR icon
8
Vor Biopharma
VOR
$1.04B
$17.9M 5.81%
+1,370,107
New +$25.5M
DNTH icon
9
Dianthus Therapeutics
DNTH
$5.68B
$14.4M 4.68%
350,000
+84,197
+32% +$3.26M
JBIO
10
Jade Biosciences
JBIO
$1.22B
$12.4M 4.03%
806,273
+173,674
+27% +$2.04M
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
$11.1M 3.59%
+685,632
New +$9.08M
CTNM
12
Contineum Therapeutics
CTNM
$526M
$9.14M 2.96%
+800,000
New +$9.13M
EPRX
13
Eupraxia Pharmaceuticals
EPRX
$380M
$9.06M 2.94%
1,200,000
– –
FULC icon
14
Fulcrum Therapeutics
FULC
$248M
$9.05M 2.93%
+800,000
New +$8.14M
NKTR icon
15
Nektar Therapeutics
NKTR
$2.39B
$8.91M 2.89%
210,732
-89,268
-30% -$5M
UPB
16
Upstream Bio Inc
UPB
$349M
$8.14M 2.64%
300,000
– –
NGNE icon
17
Neurogene
NGNE
$696M
$7.21M 2.34%
350,000
-96,814
-22% -$2.41M
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$2.65B
$6.9M 2.24%
+300,000
New +$9.87M
CNTX icon
19
Context Therapeutics
CNTX
$56.4M
$6.89M 2.23%
4,683,711
– –
CGEM icon
20
Cullinan Oncology
CGEM
$1.05B
$6.56M 2.13%
+634,032
New +$5.72M
EVMN
21
Evommune Inc
EVMN
$409M
$5.56M 1.8%
+325,000
New +$6.1M
ORKA
22
Oruka Therapeutics
ORKA
$5.56B
$5.56M 1.8%
183,330
– –
SLN
23
Silence Therapeutics
SLN
$521M
$4.91M 1.59%
+808,032
New +$5.17M
UNCY icon
24
Unicycive Therapeutics
UNCY
$148M
$4.6M 1.49%
796,558
– –
CLYM
25
Climb Bio
CLYM
$735M
$3.92M 1.27%
+979,534
New +$2.35M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
NF
Napier Financial Braintree, Massachusetts $436M AUM
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Great Point Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Great Point Partners held 42 positions worth $308M, up 27% from $242M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Great Point Partners deployed $53.9M of net new capital in Q4 2025, opening 12 new positions and adding to 6 existing holdings. Its largest new stake was Vor Biopharma: 1,370,107 shares worth $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Rezolute, an estimated $11.8M trimmed.

  • Great Point Partners's largest Q4 2025 buy was Vor Biopharma: 1,370,107 shares worth $17.9M.
  • Great Point Partners added most to Soleno Therapeutics in Q4 2025, an estimated $9.6M increase.
  • Great Point Partners's biggest Q4 2025 reduction was Rezolute, cutting an estimated $11.8M.
  • Great Point Partners fully exited Ascendis Pharma A/S in Q4 2025, selling an estimated $14.9M.
  • Great Point Partners's ten largest holdings make up 62% of its $308M portfolio in Q4 2025.
  • Great Point Partners opened 12 new positions and closed 13 in Q4 2025.
  • Great Point Partners's portfolio value rose 27% quarter-over-quarter to $308M.

Based on Great Point Partners's 13F filing for Q4 2025, filed 17 Feb 2026.